Reduced intestinal inflammation in colitis models [1][3]
In DSS and TNBS murine colitis, KPV reduced weight loss, inflammatory infiltrate, myeloperoxidase activity and pro-inflammatory cytokine expression, with earlier recovery than controls.
PrecisePep/Peptide Library/KPV
Immune & Anti-Inflammatory
KPV
Lys-Pro-Val · α-MSH (11–13) · alpha-MSH C-terminal tripeptide
The three-residue business end of alpha-MSH — an anti-inflammatory tripeptide that suppresses NF-κB from inside the cell, without the pigmentation and erectile effects that make the parent hormone unusable.
00 Overview
Alpha-MSH is a potent endogenous anti-inflammatory hormone with a problem: it also drives pigmentation, appetite suppression and erectile signalling through the melanocortin receptor family. KPV is the C-terminal tripeptide — the fragment that retains the anti-inflammatory activity while largely shedding the rest of the hormone's behaviour.
The core mechanism is unusual and worth understanding: KPV does not appear to work primarily by binding a surface receptor. It is taken up into cells — in the intestine via the PepT1 peptide transporter — and interferes with NF-κB activation intracellularly, blocking the master switch for inflammatory cytokine transcription.[1][2] That is a categorically different intervention point from a cytokine antibody or a steroid.
The research base is rodent and cell-culture: colitis models, epithelial barrier models, and antimicrobial work showing activity against bacteria and fungi at low concentrations.[3][4] There are no human trials. In the research community KPV is rarely used alone — it is best known as the "K" that turns the GLOW blend into KLOW.
// Mechanism of action
NF-κB suppression. NF-κB is the transcription factor that switches on most inflammatory cytokine production. KPV inhibits its activation and nuclear translocation, reducing TNF-α, IL-1β, IL-6 and IL-8 output at source rather than neutralising the cytokines after they are made.
PepT1-mediated uptake. In intestinal epithelial cells KPV is transported intact by PepT1 — the di/tripeptide transporter — allowing it to act intracellularly at nanomolar concentrations. PepT1 expression increases in inflamed intestinal tissue, which means the transporter concentrates the peptide precisely where inflammation is worst.[2]
Melanocortin receptor interaction. KPV retains some MC1R-related activity, which contributes to anti-inflammatory signalling in immune and epithelial cells while lacking the pigmentation-driving potency of the full hormone.
Antimicrobial activity. α-MSH-derived peptides including KPV show direct antimicrobial effects against Staphylococcus aureus and Candida albicans in vitro at low concentrations — an unusual dual property for an anti-inflammatory.[4]
Mast-cell stabilisation. Reported reduction of mast-cell degranulation, relevant to histamine-driven and allergic inflammation.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
PepT1-mediated uptake concentrates activity in inflamed tissue [2]
Demonstrated transport of intact KPV into intestinal epithelial and immune cells via PepT1, with anti-inflammatory activity at nanomolar concentrations — orders of magnitude below what a receptor-surface mechanism would require.
NF-κB pathway inhibition [1][5]
Direct demonstration of reduced NF-κB activation and nuclear translocation in stimulated epithelial and immune cells, with corresponding cytokine reduction.
Antimicrobial activity against bacteria and fungi [4]
α-MSH and its C-terminal fragments including KPV show direct killing activity against S. aureus and C. albicans in vitro.
Epithelial barrier protection [6]
α-MSH and derived peptides protect intestinal epithelial monolayers against cytokine-induced barrier damage — the mechanistic basis for gut-permeability claims.
Anti-inflammatory effect in lung and systemic models [5]
Related α-MSH tripeptides ameliorate endotoxin-induced NF-κB activation in alveolar epithelium.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Human inflammatory bowel disease application
The most mechanistically supported human hypothesis for KPV — colitis models, PepT1 upregulation in inflamed tissue, and oral bioavailability all point the same direction. No human trial exists.
Reduction of systemic inflammatory load
Extrapolated from local intestinal findings to whole-body inflammation. The systemic claim is much weaker than the intestinal one because PepT1-driven concentration is a gut-specific advantage.
Improved environment for tissue repair
The stated rationale for including KPV in KLOW: suppress the chronic inflammatory signalling that blocks resolution, so repair peptides can work. Coherent; never tested as a combination.
Mast cell activation and histamine-driven conditions
Follows from reported mast-cell stabilisation. Human evidence absent.
Topical use in inflammatory skin conditions
Psoriasis, eczema and acne have all been proposed on the basis of MC1R signalling and antimicrobial activity. Pre-clinical at best.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Reduced gut symptoms and bloating
The dominant community report, typically with oral use. Directionally consistent with the colitis literature.
Reduced joint stiffness and general inflammation markers
Reported in KLOW users, though separating KPV from the other three components in a blend is impossible by definition.
Skin improvement in inflammatory dermatoses
Occasionally reported with topical or oral use for acne and eczema.
Very few adverse reports
KPV is one of the few compounds on this site with a near-empty community adverse-effect column. That reflects low usage volume and short exposure histories as much as it reflects safety.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Well tolerated in animal models [1][3]
Rodent colitis studies report no notable toxicity at effective doses. Small studies, short durations, healthy-animal baselines.
No human safety data
No human pharmacokinetics, no clinical safety study, no long-term exposure data.
Fragment lacks parent hormone effects [7]
Unlike α-MSH or melanotan-class agonists, KPV is not reported to produce pigmentation, appetite suppression or erectile effects — one of the reasons the fragment was pursued at all.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Immunosuppression with chronic use
NF-κB suppression is not selective for unwanted inflammation. Sustained systemic suppression of the principal inflammatory transcription factor theoretically impairs infection response and immune surveillance.
Masking of an underlying condition
An effective anti-inflammatory can reduce the symptoms that would otherwise lead to diagnosis. Relevant when the inflammation being suppressed has an unexamined cause.
Residual melanocortin activity
The fragment retains some melanocortin-related activity. Whether chronic use produces any MC-mediated effect is uncharacterised.
Interaction with immunosuppressive or biologic therapy
Adding an NF-κB suppressor to established immunosuppression is an additive-risk scenario with no data at all.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Mild injection-site irritation
Reported infrequently and generally mild.
Nausea with oral dosing
Occasionally reported at higher oral amounts.
No effect
Non-response is commonly reported, particularly where the underlying problem is structural rather than inflammatory.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Rodent colitis dosing [1][2][3]
Studies typically administer KPV orally, rectally or systemically at microgram-per-kilogram to low milligram-per-kilogram levels, with effects reported at strikingly low concentrations in vitro — nanomolar in PepT1-expressing cells.
No human dose has ever been established
Every human figure in circulation is community-derived.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Oral for gut, injectable for systemic
The PepT1 mechanism is intestinal. If the target is gut inflammation, oral administration exploits the transporter directly and is the better-supported route — a distinction most community protocols ignore.
Low doses may be sufficient
Nanomolar in vitro activity argues that the milligram-level doses used in the community may be far above what the mechanism requires. Nobody has established a dose-response in humans to check.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
200–500 mcg daily subcutaneous
The typical standalone injectable range in circulation.
250–500 mcg daily oral
Used for gut-focused goals, exploiting the PepT1 route.
Blend-embedded in KLOW
Within a 3.25 mg total daily KLOW dose the KPV share is set by blend ratio.
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination studies exist
No trial or animal work combines KPV with other research peptides.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
KPV + BPC-157 + TB-500 + GHK-Cu (the KLOW rationale)
The stated sequence logic: KPV halts the inflammatory loop, TB-500 mobilises repair cells, BPC-157 builds the vascular supply, GHK-Cu lays down and remodels matrix. It is a tidy narrative built from four separate literatures; the combination itself has never been studied.
KPV + BPC-157 for gut-specific work
Two independent gut-barrier mechanisms — NF-κB suppression and mucosal/angiogenic repair. The most mechanistically defensible pairing involving KPV.
KPV with metabolic agents
Proposed for GI tolerance during incretin use. Entirely speculative.
Redundancy caution with other anti-inflammatories
Stacking KPV with corticosteroids, biologics or high-dose NSAIDs compounds immunosuppression without any characterisation of the combined effect.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The K in KLOW
KPV is what distinguishes KLOW from GLOW, and is the main reason KLOW is presented as an immunomodulatory rather than purely structural blend.
Cycled off during Wolverine phases
The stated rationale for the KLOW → Wolverine rotation includes allowing melanocortin receptor sensitivity to reset.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Short courses for flares rather than continuous suppression
If the theoretical risk of chronic NF-κB suppression is immune impairment, intermittent use targeted at inflammatory episodes carries a better risk profile than indefinite use.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Gold Standard Protocol — inside KLOW at 3.25 mg daily
KPV appears only as a blend component, cycled with the blend: four vials of KLOW, then two vials of Wolverine, then back.
4–6 week standalone courses for gut issues
Oral or injectable, reported for flare management rather than continuous use.
05b Condition-specific interest
KPV is the anti-inflammatory tail of a hormone whose other fragments do entirely different things, and most of its interesting preclinical work used routes the grey market does not use. Both facts shape everything below.
No approval, no trial
KPV is not approved anywhere and has no human trial for any indication. The literature is animal models of inflammation, particularly colitis. It received a favourable PCAC vote for the 503A Bulks List in July 2026 — which is a step in a compounding pathway, not an approval. See the regulatory status section below.
Actionable — read this first
What KPV is, and what it is not
Pathophysiology
Alpha-melanocyte-stimulating hormone is a thirteen-residue peptide with several distinct activities: pigmentation through MC1R, appetite and sexual function through MC3R and MC4R, and anti-inflammatory activity attributed largely to its C-terminal tripeptide.
Mechanistic rationale
KPV is that C-terminal tripeptide — lysine-proline-valine — and it retains the anti-inflammatory activity while lacking the pigmentary and melanocortin effects of the parent hormone. That is the design logic, and it is a good one. It is also why KPV should not be conflated with Melanotan-2 or PT-141, which are built from the same hormone and do the things KPV was truncated to avoid.
Community reports
The relationship to alpha-MSH is frequently cited by vendors and the distinction between fragments is frequently not.
Components carrying the argument: C-terminal tripeptide of alpha-MSH
Theorized — the best of the animal work
Inflammatory bowel disease
Pathophysiology
Crohn disease and ulcerative colitis are immune-mediated and relapsing, and untreated inflammation causes strictures, fistulae and bowel resection.
Mechanistic rationale
Rodent colitis models report reduced inflammation with KPV, and the more interesting work used targeted oral and colon-directed delivery — nanoparticle and hydrogel formulations designed to release the peptide at the mucosa. That is the pharmacology the data supports: local action at the inflamed surface, not systemic exposure. The mechanism runs through NF-κB and MAPK signalling and is coherent.
Community reports
Widely used in IBD alongside BPC-157, generally by subcutaneous injection, which is not the route the useful animal work used.
Components carrying the argument: NF-κB and MAPK inhibition at the mucosa
Actionable
The route question
Pathophysiology
Not a condition. A pharmacology point that applies to every entry here.
Mechanistic rationale
A tripeptide is small, and small peptides survive gastrointestinal transit better than large ones — which is why oral and colon-targeted delivery is a serious research direction for KPV rather than a marketing convenience. Injecting it subcutaneously for a gut condition delivers it everywhere except the tissue the evidence is about. Where the target is skin, topical application has the same logic. The route is not a detail here; it is most of the argument.
Community reports
Subcutaneous injection dominates community use across every indication, including the gut ones.
Components carrying the argument: Local delivery is the point
Theorized — mucosal, and unstudied in people
IBS and intestinal permeability
Pathophysiology
Intestinal permeability is measurable and genuinely altered in some conditions. The syndrome built on top of that measurement is a marketing construct rather than a diagnosis.
Mechanistic rationale
The anti-inflammatory mucosal action is a reasonable rationale for symptomatic gut conditions, and it has no human evidence. This is also the category with the largest placebo response in this library, because every endpoint is subjective and fluctuating.
Community reports
Among the most consistently positive reporting for this compound, usually as part of a KLOW protocol, which makes attribution impossible.
Components carrying the argument: Mucosal anti-inflammatory signalling
Theorized — and topical is the sensible route
Skin inflammation, eczema and wound healing
Pathophysiology
Atopic dermatitis and other inflammatory skin conditions involve barrier dysfunction with a Th2-weighted inflammatory response.
Mechanistic rationale
Alpha-MSH and its fragments have well-described anti-inflammatory activity in skin, and KPV is used topically on that basis. Topical application to inflamed skin is the version of this that makes pharmacological sense, and it avoids the systemic exposure that is neither needed nor supported.
Community reports
Used topically and in wound and post-procedure contexts, frequently in blends with GHK-Cu. Reported as calming and non-irritating.
Components carrying the argument: Cutaneous anti-inflammatory signalling
Theorized — mechanistically the right shape
Oral mucositis and other mucosal inflammation
Pathophysiology
Chemotherapy and radiotherapy-induced oral mucositis is painful, limits treatment delivery, and has few good options.
Mechanistic rationale
A locally acting mucosal anti-inflammatory is exactly the right shape of intervention for this problem, and it is the sort of application where a topical or rinse formulation would be tested if anyone were testing it. Anyone undergoing cancer treatment should raise anti-inflammatory agents with their oncology team, because interactions with treatment efficacy are a live consideration.
Community reports
Occasionally used in this context. No trial data.
Components carrying the argument: Mucosal anti-inflammatory action
Theorized — weakest entry here
Arthritis and joint inflammation
Pathophysiology
Inflammatory arthritis is immune-driven; osteoarthritis has a lower-grade synovial inflammatory component alongside cartilage loss.
Mechanistic rationale
The anti-inflammatory rationale is generic rather than joint-specific, and there is no joint-directed evidence. Where intra-articular injection is being considered, the sterility risk is the dominant consideration — a septic joint destroys cartilage in days and is a surgical emergency.
Community reports
Appears in KLOW joint protocols, which makes attribution impossible.
Components carrying the argument: Generic anti-inflammatory signalling
| Application | Route with the rationale | Evidence | The thing to know |
|---|---|---|---|
| IBD / colitis | Oral, colon-targeted | Rodent | Approved biologics have surgery-avoidance data |
| IBS / permeability | Oral | None | Largest placebo response in the library |
| Skin / eczema / wounds | Topical | Preclinical | Topical is the version that makes sense |
| Oral mucositis | Topical / rinse | None | Raise with oncology before use |
| Arthritis | — | None | Intra-articular injection risks a septic joint |
| Relationship to Melanotan | — | — | Same parent hormone, truncated to avoid those effects |
What actually has evidence for these conditions
For inflammatory bowel disease: mesalazine, corticosteroids for induction, thiopurines, methotrexate, and the biologic classes — anti-TNF, anti-integrin, anti-IL-12/23 and JAK inhibitors — all with trial data on mucosal healing and avoiding surgery. Exclusive enteral nutrition has real evidence in paediatric Crohn disease. Untreated inflammation costs bowel.
For IBS: a structured low-FODMAP trial with reintroduction, soluble fibre, and gut-directed cognitive behavioural therapy or hypnotherapy, which has better evidence than most drug options. Excluding coeliac disease and IBD first matters more than the choice of treatment.
For atopic dermatitis: emollients and topical corticosteroids remain the foundation, with topical calcineurin inhibitors, and dupilumab or JAK inhibitors in moderate to severe disease — which have transformed outcomes in a condition that was poorly served for decades.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Supplied lyophilised, commonly 10 mg per vial. A tripeptide is chemically simple and dissolves readily in bacteriostatic water.
Storage
Lyophilised: refrigerated or frozen. Reconstituted: 2–8 °C.
Common vial sizes
Commonly 10 mg lyophilised vials; also supplied in oral capsule form.
Stability notes
Short peptides are generally more stable than long ones, but sterility remains the governing concern for injectable use.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved for human use. Supplied as a research chemical. KPV has appeared in some compounding-pharmacy and wellness-clinic contexts in oral form; that does not constitute regulatory approval and the regulatory position on peptide compounding has tightened considerably.
Regulatory update — current as at August 2026
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend KPV for inclusion on the Section 503A Bulks List (8–6, one abstention). It was one of six peptides recommended — alongside BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — out of seven considered.
This followed the FDA's announcement of 15 April 2026 removing twelve peptides from Category 2, the designation for substances judged to raise significant safety concerns. That removal stripped away the basis for enforcement against compounders but did not itself authorise anything, leaving these compounds in a regulatory grey area pending the PCAC review.
A PCAC recommendation is not an approval, and the 503A Bulks List is not a drug approval either. It is also worth knowing that July 2026 was the second round: across two sittings in October and December 2024 the same committee reviewed seven substances — among them ipamorelin, kisspeptin-10, AOD-9604, CJC-1295 and thymosin alpha-1 — and rejected all seven. Two separate things are being conflated in almost every write-up of the 2026 decision:
- The vote is advisory. PCAC recommendations are non-binding. The pathway from here runs: removal from Category 2 (done, April 2026) → PCAC recommendation (done, July 2026) → placement in Category 1 through notice-and-comment rulemaking, which commonly takes eight to twelve months → and the HHS Secretary must sign off on any addition to the list. Nothing is lawfully compoundable on the strength of the vote alone.
- Even a successful listing would not make these approved drugs. Inclusion on the 503A Bulks List permits a licensed compounding pharmacy to use the substance in a compounded preparation for an individual patient with a prescription. It says nothing about the compound being demonstrated safe and effective — no efficacy trial is required, and none of these has one.
- It would not legitimise research-chemical supply. A compounding pathway runs through a licensed pharmacy and a prescriber. Grey-market vials labelled "research use only" are not that, and nothing in this decision changes their status.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: PCAC vote 23-24 July 2026 and the 503A pathway. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
Athletes subject to WADA, USADA, UKAD, NCAA or military testing should assume any peptide is prohibited unless they have verified otherwise against the current WADA Prohibited List. Several classes here (growth-hormone secretagogues, TB-4 analogues, metabolic modulators) are explicitly named. Check the current list — it is republished annually.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008.Pre-clinical / animal study
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.Pre-clinical / animal study
- PubMed: KPV tripeptide — inflammation, colitis and barrier function (live query)Database or literature search
- Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000.In vitro / cell study
- Moustafa M, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003.In vitro / cell study
- Alpha-Melanocyte Stimulating Hormone Protects against Cytokine-Induced Barrier Damage in Caco-2 Intestinal Epithelial Monolayers. PLoS One. 2017.In vitro / cell study
- Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Review.Review or meta-analysis
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.